Table 5.
Differences in treatment before and after 1990
| Before 1990 (n=15) | 1990 and afterward (n=95) | |
|---|---|---|
| Treatment received? | Unknown = 1/15 (7%) | Unknown = 5/95 (5%) |
| Yes = 14/15 (93%) | Yes = 69/90 (77%) | |
| No = 0/15 (0%) | No = 21/90 (23%) | |
| Ventricular reservoir placed? | Unknown = 0/15 (0%) | Unknown = 6/95 (6%) |
| Yes = 12/15 (80%) | Yes = 48/89 (54%) | |
| No = 3/15 (20%) | No = 41/89 (46%) | |
| Radiation for LM? | Unknown = 0/15 (0%) | Unknown = 7/95 (7%) |
| Yes = 11/15 (73%) | Yes = 37/88 (42%) | |
| No = 4/15 (27%) | No = 51/88 (58%) | |
| Brain | 5/15 (33%) | 20/88 (23%) |
| Spine | 3/15 (20%) | 11/88 (13%) |
| Brain and spine | 3/15 (20%) | 6/88 (7%) |
| Systemic chemotherapy for LM? | Unknown = 1/15 (7%) | Unknown = 8/95 (8%) |
| Yes = 4/14 (29%) | Yes = 38/87 (44%) | |
| No = 10/14 (71%) | No = 49/87 (56%) | |
| Systemic therapies used | ||
| Dacarbazine | 2/14 (14%) | 2/87 (2%) |
| Carmustine or lomustine | 3/14 (21%) | 2/87 (2%) |
| Hydroxyurea | 1/14 (7%) | 1/87 (1%) |
| CVD | 1/14 (7%) | 5/87 (6%) |
| Cisplatin | 1/14 (7%) | 1/87 (1%) |
| Tamoxifen | 1/14 (7%) | 1/87 (1%) |
| Velban | 0 | 1/87 (1%) |
| Procarbazine | 0 | 20/87 (23%) |
| Interleukin-2 | 0 | 3/87 (3%) |
| Interferon-α | 0 | 3/87 (3%) |
| Temozolomide | 0 | 8/87 (9%) |
| Paclitaxel | 0 | 1/87 (1%) |
| Fotemustine | 0 | 1/87 (1%) |
| Thalidomide | 0 | 6/87 (7%) |
| Intrathecal chemotherapy? | Unknown = 1/15 (7%) | Unknown = 7/95 (7%) |
| Yes = 12/14 (86%) | Yes = 41/88 (47%) | |
| No = 2/14 (14%) | No = 47/88 (53%) | |
| Intrathecal therapies used | ||
| Cytarabine | 3/14 (21%) | 3/88 (3%) |
| Methotrexate | 6/14 (43%) | 9/88 (10%) |
| Thiotepa | 1/14 (7%) | 1/88 (1%) |
| Interferon-α | 1/14 (7%) | 0 |
| LAK cells | 1/14 (7%) | 0 |
| Interleukin 2 | 3/14 (21%) | 31/88 (35%) |
| [131I]NaI | 0 | 1/88 (1%) |
| Topotecan | 0 | 3/88 (3%) |
Abbreviations: LM, leptomeningeal melanomatosis; CVD, cisplatin, vinblastine, dacarbazine; LAK, lymphokine-activated killer.